

VOLITIONRX LTD  
Form 8-K  
May 15, 2015

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): May 15, 2015 (May 12, 2015)

**VolitionRx Limited**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of Incorporation)

**000-30402**  
(Commission File Number)

**91-1949078**  
(IRS Employer  
Identification Number)

**1 Scotts Road**

**#24-05 Shaw Centre**

**Singapore 228208**  
(Address of principal executive offices)

**Telephone: +1 (646) 650-1351**

**Facsimile: +32 8172 5651**  
(Registrant's Telephone and Facsimile  
Number)

Edgar Filing: VOLITIONRX LTD - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

**VOLITIONRX LIMITED**

**Form 8-K**

**Current Report**

**Item 2.02. Results of Operations and Financial Condition.**

The following information is being furnished in accordance with General Instruction B.2. of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the Securities Act ), or the Exchange Act, except as expressly set forth by specific reference in such filing:

On May 12, 2015, VolitionRx Limited hosted a conference call discussing its financial results for the quarter ended March 31, 2015. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the transcript of the conference call.

**Item 9.01. Financial Statements and Exhibits.**

(d)

Exhibits.

**Exhibit**

**Number Description of Exhibit**

99.1 First Quarter 2015 Financial Earnings and Business Update Conference Call Transcript dated May 12, 2015<sup>(1)</sup>

(1)Reference is made to the Exhibit Index hereto with respect to the exhibits furnished herewith. The exhibits listed in the Exhibit Index hereto are being furnished in accordance with General Instruction B.2. of Form 8-K and shall not be deemed filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed to be incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.



**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

VOLITIONRX LIMITED

Date: May 15, 2015

By: /s/ Cameron Reynolds  
Cameron Reynolds  
Chief Executive Officer & President